Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F.

J Clin Invest. 2018 Jun 4. pii: 98765. doi: 10.1172/JCI98765. [Epub ahead of print]

2.

Bloodless tandem autologous transplant in Jehovah's Witness patients.

Khan R, Mott SL, Schultz A, Jethava YS, Tricot G.

Bone Marrow Transplant. 2018 May 24. doi: 10.1038/s41409-018-0132-6. [Epub ahead of print]

PMID:
29795417
3.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S.

Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. No abstract available.

4.

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma.

Zhan X, Yu W, Franqui-Machin R, Bates ML, Nadiminti K, Cao H, Amendt BA, Jethava Y, Frech I, Zhan F, Tricot G.

Oncotarget. 2017 Nov 27;8(67):111213-111224. doi: 10.18632/oncotarget.22740. eCollection 2017 Dec 19.

5.

Kinetic fragility and structure of lithium borophosphate glasses analysed by 1D/2D NMR.

Muñoz-Senovilla L, Tricot G, Muñoz F.

Phys Chem Chem Phys. 2017 Aug 30;19(34):22777-22784. doi: 10.1039/c7cp04171c.

PMID:
28828426
6.

Drug Combinations with Transplantation for Myeloma.

Jethava YS, Barlogie B, Tricot GJ.

N Engl J Med. 2017 Jul 6;377(1):91-2. doi: 10.1056/NEJMc1705671. No abstract available.

7.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F.

Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. No abstract available.

8.

3D correlation NMR spectrum between three distinct heteronuclei for the characterization of inorganic samples: Application on sodium alumino-phosphate materials.

Nagashima H, Tricot G, Trébosc J, Lafon O, Amoureux JP, Pourpoint F.

Solid State Nucl Magn Reson. 2017 Jul - Aug;84:164-170. doi: 10.1016/j.ssnmr.2017.03.002. Epub 2017 Mar 22.

PMID:
28351540
9.

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.

Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F.

EBioMedicine. 2017 Apr;18:41-49. doi: 10.1016/j.ebiom.2017.02.011. Epub 2017 Feb 16.

10.

Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC).

Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BCH, Spinelli JJ, Becker N, Benhaim-Luzon V, Bhatti P, Boffetta P, Brennan P, Brown EE, Cocco P, Costas L, Cozen W, de Sanjosé S, Foretová L, Giles GG, Maynadié M, Moysich K, Nieters A, Staines A, Tricot G, Weisenburger D, Zhang Y, Baris D, Purdue MP.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):876-885. doi: 10.1158/1055-9965.EPI-16-0762-T. Epub 2017 Feb 21.

11.

Non-homogeneous distribution of Al3+ in doped phosphate glasses revealed by 27Al/31P solid state NMR.

Tricot G, Doumert B, Revel B, Bria M, Trebosc J, Vezin H.

Solid State Nucl Magn Reson. 2017 Jul - Aug;84:137-142. doi: 10.1016/j.ssnmr.2017.02.003. Epub 2017 Feb 9.

PMID:
28209384
12.

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G.

Onco Targets Ther. 2017 Jan 6;10:217-226. doi: 10.2147/OTT.S112423. eCollection 2017.

13.

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.

Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F.

J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4.

14.

The structure of Pyrex® glass investigated by correlation NMR spectroscopy.

Tricot G.

Phys Chem Chem Phys. 2016 Sep 29;18(38):26764-26770.

PMID:
27711426
15.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

16.

Reply.

Ince MN, Blazar BR, Edmond MB, Tricot G, Wannemuehler MJ.

Inflamm Bowel Dis. 2016 Aug;22(8):E27-8. doi: 10.1097/MIB.0000000000000861. No abstract available.

PMID:
27416042
17.

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ.

Br J Haematol. 2016 Oct;175(1):87-101. doi: 10.1111/bjh.14199. Epub 2016 Jun 22.

18.

Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.

Abbi KK, Silverman M, Farooq U, Tricot A, Dozeman L, Nadiminti K, Krasowski MD, Tricot GJ.

Br J Haematol. 2016 Aug;174(4):536-40. doi: 10.1111/bjh.14081. Epub 2016 May 12.

PMID:
27172326
19.

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S.

Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9.

20.

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.

Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD.

Oncotarget. 2016 Jan 12;7(2):1598-607. doi: 10.18632/oncotarget.6408.

21.

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST.

Oncotarget. 2015 Dec 1;6(38):41275-89. doi: 10.18632/oncotarget.5753.

22.

A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium.

Costas L, Lambert BH, Birmann BM, Moysich KB, De Roos AJ, Hofmann JN, Baris D, Wang SS, Camp NJ, Tricot G, Atanackovic D, Brennan P, Cocco P, Nieters A, Becker N, Maynadié M, Foretová L, Boffetta P, Staines A, Brown EE, de Sanjosé S.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):217-21. doi: 10.1158/1055-9965.EPI-15-0953. Epub 2015 Oct 13.

23.

Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation.

Ince MN, Blazar BR, Edmond MB, Tricot G, Wannemuehler MJ.

Inflamm Bowel Dis. 2016 Jan;22(1):194-201. doi: 10.1097/MIB.0000000000000599. Review.

24.

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G.

Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800. Review.

25.

Adoptive B-cell transfer mouse model of human myeloma.

Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S.

Leukemia. 2016 Apr;30(4):962-6. doi: 10.1038/leu.2015.197. Epub 2015 Jul 23. No abstract available.

26.

Intermediate length scale organisation in tin borophosphate glasses: new insights from high field correlation NMR.

Tricot G, Saitoh A, Takebe H.

Phys Chem Chem Phys. 2015 Nov 28;17(44):29531-40. doi: 10.1039/c5cp02095f. Epub 2015 Jul 17.

PMID:
26186677
27.

NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.

Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F.

Clin Cancer Res. 2015 Dec 15;21(24):5532-42. doi: 10.1158/1078-0432.CCR-15-0254. Epub 2015 Jul 8.

28.

P-O-B(3) linkages in borophosphate glasses evidenced by high field (11)B/(31)P correlation NMR.

Tricot G, Raguenet B, Silly G, Ribes M, Pradel A, Eckert H.

Chem Commun (Camb). 2015 Jun 7;51(45):9284-6. doi: 10.1039/c5cc01992c.

PMID:
25891539
29.

Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.

Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H, Shi J, De Domenico I, Tricot G, Zhan F.

Cancer Res. 2015 Jun 1;75(11):2211-21. doi: 10.1158/0008-5472.CAN-14-3804. Epub 2015 Apr 8.

30.

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S.

Exp Hematol Oncol. 2015 Mar 27;4:9. doi: 10.1186/s40164-015-0005-2. eCollection 2015.

31.

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.

Hansson M, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G.

Clin Cancer Res. 2015 Jun 15;21(12):2730-6. doi: 10.1158/1078-0432.CCR-14-3090. Epub 2015 Feb 24.

32.

Red coralline algae assessed as marine pH proxies using 11B MAS NMR.

Cusack M, Kamenos NA, Rollion-Bard C, Tricot G.

Sci Rep. 2015 Feb 2;5:8175. doi: 10.1038/srep08175.

33.

Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.

Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F.

Cancer Res. 2015 Feb 1;75(3):594-604. doi: 10.1158/0008-5472.CAN-14-2362. Epub 2015 Jan 14.

34.

A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium.

Andreotti G, Birmann BM, Cozen W, De Roos AJ, Chiu BC, Costas L, de Sanjosé S, Moysich K, Camp NJ, Spinelli JJ, Pahwa P, Dosman JA, McLaughlin JR, Boffetta P, Staines A, Weisenburger D, Benhaim-Luzon V, Brennan P, Costantini AS, Miligi L, Campagna M, Nieters A, Becker N, Maynadié M, Foretová L, Zheng T, Tricot G, Milliken K, Krzystan J, Steplowski E, Baris D, Purdue MP.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):631-4. doi: 10.1158/1055-9965.EPI-14-1145. Epub 2014 Dec 23.

35.

Nek2 is a novel regulator of B cell development and immunological response.

Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F.

Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17.

36.

Inhibition of Nek2 by small molecules affects proteasome activity.

Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ.

Biomed Res Int. 2014;2014:273180. doi: 10.1155/2014/273180. Epub 2014 Sep 17.

37.

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F.

Oncotarget. 2014 Dec 15;5(23):11986-97.

38.

Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1949-57. doi: 10.1016/j.bbmt.2014.08.007. Epub 2014 Aug 16.

39.

Impact of root-induced mobilization of zinc on stable Zn isotope variation in the soil-plant system.

Houben D, Sonnet P, Tricot G, Mattielli N, Couder E, Opfergelt S.

Environ Sci Technol. 2014 Jul 15;48(14):7866-73. doi: 10.1021/es5002874. Epub 2014 Jul 3.

PMID:
24955480
40.

Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients.

Long G, Waller EK, Gregurek S, Tricot G, Marschner S, Bill J.

J Clin Apher. 2015 Feb;30(1):1-7. doi: 10.1002/jca.21341. Epub 2014 Jun 19.

PMID:
24941931
41.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S.

Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x. Review.

42.

Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma.

Kim JH, Goulston C, Zangari M, Tricot G, Boyer MW, Hanson KE.

Transpl Infect Dis. 2014 Jun;16(3):421-9. doi: 10.1111/tid.12225. Epub 2014 May 5.

PMID:
24797543
43.

Heteronuclear NMR spectroscopy as a surface-selective technique: a unique look at the hydroxyl groups of γ-alumina.

Taoufik M, Szeto KC, Merle N, Del Rosal I, Maron L, Trébosc J, Tricot G, Gauvin RM, Delevoye L.

Chemistry. 2014 Apr 1;20(14):4038-46. doi: 10.1002/chem.201304883. Epub 2014 Mar 6.

PMID:
24604836
44.

Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ.

Bone. 2014 Apr;61:39-43. doi: 10.1016/j.bone.2013.12.025. Epub 2013 Dec 31.

45.

ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma.

Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J, Zhan F.

Leukemia. 2014 May;28(5):1155-8. doi: 10.1038/leu.2013.383. Epub 2013 Dec 24. No abstract available.

46.

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S.

Blood Cancer J. 2013 Nov 29;3:e165. doi: 10.1038/bcj.2013.61.

47.

A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium.

Andreotti G, Birmann B, De Roos AJ, Spinelli J, Cozen W, Camp NJ, Moysich K, Chiu B, Steplowski E, Krzystan J, Boffetta P, Benhaim-Luzon V, Brennan P, de Sanjosé S, Costas L, Costantini AS, Miligi L, Cocco P, Becker N, Foretová L, Maynadié M, Nieters A, Staines A, Tricot G, Milliken K, Weisenburger D, Zheng T, Baris D, Purdue MP.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1620-7. doi: 10.1158/1055-9965.EPI-13-0334. Epub 2013 Aug 20.

48.

RARα2 expression confers myeloma stem cell features.

Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G.

Blood. 2013 Aug 22;122(8):1437-47. doi: 10.1182/blood-2013-02-482919. Epub 2013 Jul 11.

49.

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.

Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ.

Bone Marrow Transplant. 2013 Nov;48(11):1444-9. doi: 10.1038/bmt.2013.80. Epub 2013 Jun 10.

50.

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.

Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Mårtensson L, Teige I, Tricot G, Frendéus B.

Cancer Cell. 2013 Apr 15;23(4):502-15. doi: 10.1016/j.ccr.2013.02.026.

Supplemental Content

Loading ...
Support Center